N-Methyl-4-chloropyridine-2-carboxamide CAS NO.220000-87-3

N-methyl-4-chloro-2-pyridinecarbonamide Properties Melting point 41-43 ° C Boiling point 317.8 ± 27.0 ° C (Predicted) Density 1.264 ± 0.06g/cm3 (Predicted) Storage conditions Keepinmarkplace, Sealeddry, RoomTemperature Solubility Chloroform (Slightly), Chloroethane (Slightly), EthylAcetate (Slightly), Met form Solid acidity coefficient (pKa) 13.41 ± 0.46 (Predicted) Color Off WhitetoLightYellowCAS database 220000-87-3 (CASDataBaseReference) N-methyl-4-chloro-2-pyridinecarbonamide Application and synthesis method Introduction N-methyl-4-chloro-2-pyridinecarbonamide is a white powder substance, which is an intermediate of sorafenib, a clinical anticancer drug substance used for the treatment of liver and renal cell cancer; Sorafenib intermediate. The application of N-methyl-4-chloro-2-pyridinecarbonamide can be used as an intermediate for organic synthesis and pharmaceutical intermediates, mainly used in laboratory research and development processes and chemical and pharmaceutical synthesis processes.

N-methyl-4-chloro-2-pyridinecarbonamide Properties Melting point 41-43 ° C Boiling point 317.8 ± 27.0 ° C (Predicted) Density 1.264 ± 0.06g/cm3 (Predicted) Storage conditions Keepinmarkplace, Sealeddry, RoomTemperature Solubility Chloroform (Slightly), Chloroethane (Slightly), EthylAcetate (Slightly), Met form Solid acidity coefficient (pKa) 13.41 ± 0.46 (Predicted) Color Off WhitetoLightYellowCAS database 220000-87-3 (CASDataBaseReference) N-methyl-4-chloro-2-pyridinecarbonamide Application and synthesis method Introduction N-methyl-4-chloro-2-pyridinecarbonamide is a white powder substance, which is an intermediate of sorafenib, a clinical anticancer drug substance used for the treatment of liver and renal cell cancer; Sorafenib intermediate. The application of N-methyl-4-chloro-2-pyridinecarbonamide can be used as an intermediate for organic synthesis and pharmaceutical intermediates, mainly used in laboratory research and development processes and chemical and pharmaceutical synthesis processes.